Abstract

Purpose. Nonalcoholic fatty liver disease (NAFLD) is a progressive and intractable disease associated with metabolic syndrome. Red yeast rice (RYR) contains monacolin K, a potent inhibitor of HMG-CoA reductase, and its consumption decreases cholesterol and triglyceride levels. We examined the efficacy of RYR constituents using a novel metabolic syndrome-NAFLD mouse model (MSG mice). Methods. Two types of RYR grown under different culture conditions were used. 1P-DU contained only 0.002 g/100 g of monacolin K, whereas 3P-D1 contained 0.131 g/100 g. MSG mice were divided into three groups: control (C) group fed standard food, RYR-C group fed standard food with 1% 1P-DU, and RYR-M group fed standard food with 1% 3P-D1. Mice were examined from 12 to 24 weeks of age. Results. Serum insulin, leptin, and liver damage as well as macrophage aggregation in visceral fat in RYR-C and RYR-M groups were lower than those in C group. The serum adiponectin levels in RYR-C group were significantly higher than those in RYR-M and C groups. Conclusions. RYR was effective against obesity-related inflammation, insulin resistance, and NAFLD in MSG mice irrespective of monacolin K levels. GABA and various peptides produced during fermentation were determined as the active constituents of RYR.

Highlights

  • Nonalcoholic fatty liver disease (NAFLD) is a phenotype of the metabolic syndrome in the liver

  • We examined the efficacy of Red yeast rice (RYR) constituents using a novel metabolic syndrome-NAFLD mouse model (MSG mice)

  • 31% of NAFLD cases progress to nonalcoholic steatohepatitis (NASH), which is a severe form of NAFLD [1]

Read more

Summary

Introduction

Nonalcoholic fatty liver disease (NAFLD) is a phenotype of the metabolic syndrome in the liver. 31% of NAFLD cases progress to nonalcoholic steatohepatitis (NASH), which is a severe form of NAFLD [1]. Approximately 20% of NASH cases progress to liver cirrhosis after 10 years [2]. Histopathological evaluation of the liver is necessary for diagnosis of NASH, and no noninvasive diagnostic procedure is currently available. Weight loss through lifestyle changes such as regular exercise and diet is considered as the main treatment strategy for NAFLD/NASH, it has been shown that 50% or more of NAFLD/NASH cases could not enhance and maintain an improved lifestyle [3]. The Evidence-Based Complementary and Alternative Medicine drugs pioglitazone and candesartan have been suggested for treatment of NAFLD/NASH [4, 5]; no therapeutic drug has currently been established

Objectives
Methods
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call